Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Current Assets: 2023-2025

Historic Current Assets for Zenas BioPharma (ZBIO) over the last 1 years, with Sep 2025 value amounting to $296.6 million.

  • Zenas BioPharma's Current Assets fell 24.67% to $296.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $296.6 million, marking a year-over-year decrease of 24.67%. This contributed to the annual value of $355.9 million for FY2024, which is 495.15% up from last year.
  • According to the latest figures from Q3 2025, Zenas BioPharma's Current Assets is $296.6 million, which was up 6.47% from $278.6 million recorded in Q2 2025.
  • Over the past 5 years, Zenas BioPharma's Current Assets peaked at $393.8 million during Q3 2024, and registered a low of $59.8 million during Q4 2023.
  • Moreover, its 3-year median value for Current Assets was $307.2 million (2025), whereas its average is $283.8 million.
  • Its Current Assets has fluctuated over the past 5 years, first surged by 495.15% in 2024, then declined by 24.67% in 2025.
  • Quarterly analysis of 3 years shows Zenas BioPharma's Current Assets stood at $59.8 million in 2023, then surged by 495.15% to $355.9 million in 2024, then dropped by 24.67% to $296.6 million in 2025.
  • Its Current Assets was $296.6 million in Q3 2025, compared to $278.6 million in Q2 2025 and $317.8 million in Q1 2025.